

## Press Cutting

Citigate  
Dewe Rogerson

Client: Chi-Med

Publication: Shares

Date: 7 October 2014

# SHARES

## CHI-MED TO GIVE DRUG R&D BRIEFING

Tue 07 Oct 2014 08:32

Hutchison China MediTech will host a briefing to update analysts and investors on Hutchison MediPharma Ltd, its majority owned pharmaceutical R&D division, in London on 17 October.

HMP has a substantial pipeline of oral, small molecule and botanical drugs for cancer and inflammatory diseases that has grown and progressed significantly in recent years.

HMP's current clinical pipeline includes: fruquintinib, sulfatinib, epitinib, theliatinib, and AZD6094 (formerly known as volitinib), each of which has the potential to treat a number of cancers. The clinical pipeline also includes HMPL-523 and HMPL-004, which have potential to treat certain inflammatory conditions. The briefing will focus on this pipeline.

During the briefing, the management team will detail the key aspects of HMP's R&D strategy and focus, as well as providing further information on some of HMP's pre-clinical research programmes, including its PI3K inhibitor and its FGFR inhibitor.

No new material trading or financial information will be disseminated at the meeting. Following the meeting, the presentations will be made available at <http://chi-med.com/eng/irinfo/presentations.htm>. The briefing will be held at the Andaz Hotel, 40 Liverpool Street, London, EC2M 7QN, on 17 October at 9:30 a.m., with registration starting from 9:15 a.m.

At 8:32am: (LON:HCM) Hutchison China Meditech Ltd share price was +10p at 1140p

### Hutchison China Meditech (HCM)

1,140.00p 0.00p (0.00%) delayed 08:00AM

Price delayed by 15 minutes.

